Spots Global Cancer Trial Database for First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Official Title: A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors
Study ID: NCT04761601
Conditions
Study Description
Brief Summary: This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
Torrance Memorial, Torrance, California, United States
Winship Institute of Emory University, Atlanta, Georgia, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Sarah Cannon, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Contact Details
Name: Stephen Letrent, PharmD, PhD
Affiliation: 1200 Pharma, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
